PROCEPT BioRobotics Corporation PRCT
23.34 USD +0.29 (+1.26%)
At closeNov 11, 2026, 4:50 PM EST
23.00 -0.34 -1.46%
After hours · Nov 11, 4:50 PM ET
22.55 Day range 23.36
16.67 52-week range 38.11
- YTD
- -25.81%
- 1 year
- -25.53%
News
benzinga.com Truist Securities Maintains Hold on PROCEPT BioRobotics, Raises Price Target to $24 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Hold and raises the price target from $21 to $24.
benzinga.com UBS Maintains Neutral on PROCEPT BioRobotics, Raises Price Target to $21 UBS analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral and raises the price target from $20 to $21.
benzinga.com Leerink Partners Maintains Market Perform on PROCEPT BioRobotics, Raises Price Target to $22 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Market Perform and raises the price target from $20 to $22.
marketbeat.com PROCEPT BioRobotics Q3 Earnings Call Highlights PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements…
seekingalpha.com PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
zacks.com PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.
benzinga.com PROCEPT BioRobotics Q3 2026 Earnings Call Transcript PROCEPT BioRobotics (NASDAQ:PRCT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $395.409M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $395.409 million estimate.
globenewswire.com PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing…
zacks.com PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com Important Notice to Long-Term Shareholders of Beta Bionics, Inc. (NASDAQ: BBNX); GoDaddy Inc. (NYSE: GDDY); Hub Group, Inc. (NASDAQ: HUBG); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ: BBNX): Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX). What is…
seekingalpha.com PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial…
gurufocus.com PROCEPT BioRobotics Corp (PRCT) Shares Surge 4.0% -- What GF Score of 71 Tells Investors On October 19, 2026, PROCEPT BioRobotics Corp (PRCT) shares rose 4.0% to a current price of $18.28. This price is within a 52-week range of $16.67 to $38.11, re
globenewswire.com PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026 SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing…- benzinga.com Barclays Initiates Coverage On PROCEPT BioRobotics with Overweight Rating, Announces Price Target of $30 Barclays analyst Christopher Pasquale initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight rating and announces Price Target of $30.
prnewswire.com PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit has been filed concerning certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT).…
globenewswire.com LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation A lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation
defenseworld.net PROCEPT BioRobotics (NASDAQ:PRCT) & Varex Imaging (NASDAQ:VREX) Critical Analysis Varex Imaging (NASDAQ: VREX - Get Free Report) and PROCEPT BioRobotics (NASDAQ: PRCT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT).…
newsfilecorp.com Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Take Immediate Action in the Securities Class Action Before September 22, 2026 New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the…
globenewswire.com Portnoy Law Firm Announces Class Action on Behalf of PROCEPT BioRobotics Corporation Investors LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PROCEPT BioRobotics Corporation, (“PROCEPT” or the "Company") (NASDAQ: PRCT) investors of a class action on behalf of…
prnewswire.com PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ: PRCT ) violations…
newsfilecorp.com Kaplan Fox Alerts PROCEPT BioRobotics Corporation (PRCT) Investors With Losses to a Securities Class Action - Act Before the September 22, 2026 Deadline New York, New York--(Newsfile Corp. - September 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the…
prnewswire.com PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit NEW YORK, Sept. 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February…
globenewswire.com Deadline Alert: PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit LOS ANGELES, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 22, 2026 deadline to file a lead plaintiff motion in the class action…
businesswire.com PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of PROCEPT BioRobotics…
benzinga.com TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28 TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $34 to $28.
benzinga.com Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25 Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
benzinga.com Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23 Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.- benzinga.com William Blair Downgrades PROCEPT BioRobotics to Market Perform William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $397.424M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $397.424 million estimate.
- benzinga.com PROCEPT BioRobotics Q2 EPS $(0.47) Misses $(0.46) Estimate, Sales $94.498M Beat $92.893M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent. This is a 34.29 percent decrease over losses…
benzinga.com Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25 Truist Securities analyst Richard Newitter downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Hold and lowers the price target from $30 to $25.
benzinga.com This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Wall Street analysts upgraded various top stocks, including Nucor, Varonis, Invitation Homes, and Macerich. See what experts say about NUE.
benzinga.com This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts changed outlook on top names, see all changes on Benzinga's analyst ratings page. Check out views on BB, SLGL, PRCT, OGE, TTWO.- benzinga.com Evercore ISI Group Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $30 Evercore ISI Group analyst Vijay Kumar initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform rating and announces Price Target of $30.
benzinga.com Top 3 Health Care Stocks You'll Regret Missing In Q2 Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.
benzinga.com This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page and analysts' views before buying MKTX stock.- benzinga.com Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29 Leerink Partners analyst Mike Kratky downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform and lowers the price target from $31 to $29.
benzinga.com PROCEPT BioRobotics Announces Two Milestones In Its WATER IV Prostate Cancer Clinical Program PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation®…- benzinga.com Piper Sandler Reiterates Overweight on PROCEPT BioRobotics, Raises Price Target to $35 Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $28 to $35.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com PROCEPT BioRobotics Affirms FY2026 Sales Guidance of $390.000M-$410.000M vs $396.674M Est PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2026 sales outlook from $390.000 million-$410.000 million to $390.000 million-$410.000 million vs $396.674 million estimate.
- benzinga.com PROCEPT BioRobotics Q1 EPS $(0.56), Inline, Sales $83.132M Beat $80.506M Estimate PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.56) per share which met the analyst consensus estimate. This is a 24.44 percent decrease over losses of $(0.45) per share from the…
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com Baird Initiates Coverage On PROCEPT BioRobotics with Neutral Rating, Announces Price Target of $30 Baird analyst David Rescott initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Neutral rating and announces Price Target of $30.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Truist Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $30 Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $47 to $30.
benzinga.com Leerink Partners Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $30 Leerink Partners analyst Mike Kratky maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $55 to $30.